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Abstract
Background: The novel coronavirus disease (COVID-19) outbreak has halted activities
throughout the globe because of its rapid spread. COVID-19 is caused by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) a β-coronavirus first detected
in China. SARS-CoV-2 has been implicated to be transmitted via direct contact, fomite,
respiratory droplets, and possibly aerosol. The spread of the disease is complicated
due to the slow onset of symptoms and asymptomatic infected patients.
Methods: This narrative communication summarizes the recent researches sourced
using sensitive search strategies to identify COVID-19 current perspectives on the
control, prevention, and therapeutic promise.
Result: Several strategies and multiple control measures have been implemented
around the globe to contain COVID-19. Considering the exponential spread of the
pandemic, several scientists and physicians have been racing to discover possible
therapeutics and vaccines for COVID-19. There are clinical trials to investigate the
vaccine designed to protect against the infection and also to substantiate the claim
made for BCG protection against COVID-19. Although, there is currently no universally
approved medication to treat SARS-CoV-2, there have been random reports of existing
medications ameliorating the infection, and these regimens are still under clinical trial.
There is also the potential therapeutic prospect of rhinothermy to fight SARS-CoV-2
judging from its success in fighting upper respiratory tract viral infection.
Conclusion: The information provided in this communication gives a reliable
intellectual grounding regarding the current perspective on COVID-19 control, progress
made in the development of vaccines and therapeutic regimen, and where future
research in this area should be focused.
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1. Introduction
1.1. SARS-CoV-2
Coronavirus disease 2019 (COVID-19) is a novel strain of coronaviruses (CoV) and
was first identified amidst an investigation that lead into an outbreak in Wuhan City,
Hubei Province, China in late December 2019. COVID-19 was initially called 2019-nCoV,
however, it was renamed as SARS-CoV-2 by the World Health Organization (WHO) on
February 12, 2020. Due to its exponential spread, SARS-CoV-2 was labelled as a Public
Health Emergency of International Concern by the International Health Regulations
Committee of the WHO on January 30, 2020. SARS-CoV-2 is a β-coronavirus which is
a single-stranded positive-sense RNA virus belonging to a group within the subgenus
S arbecovirus, Orthocoronavirinae subfamily [1, 2].
The symptoms of SARS-CoV-2 infection may include: fever, shortness of breath,
tiredness, dry cough, aches and pain, sore throat, and few may experience diarrhea,
nausea, or a runny nose [3]. People with underlying medical conditions and the elderly
have a higher risk of developing severe disease and death [3]. While some carriers could
be asymptomatic, they are contagious as the onset of symptoms ranges between one
and 14 days, or even more [4]. SARS-CoV-2 is thought to be transmitted through direct
contact, fomite, fecal, and respiratory droplets [5]. Recently, there have been emerging
suggestions that SARS-CoV-2 can exist as an aerosol under very limited conditions
as the virus particles on droplets of mucus or saliva could be suspended in the air
for a few seconds, and that anyone passing through that pathogenic cloud could be
vulnerable to the infection. The result of experimental procedure evaluating SARS-CoV-
2 and SARS-CoV-1 stability in aerosols and other surfaces indicates that fomite and
aerosol transmission of SARS-CoV-2 are possible, as SARS-CoV-2 could remain viable
and virulent in aerosols for hours and on surfaces for days, and this is comparable to
the transmission of SARS-CoV-1 [5].
As of June 10, 2020, according to the WHO COVID-19 Situation Report-141, a total of
7,039,918 cases were confirmed and a total of 404,396 deaths had resulted from the
COVID-19 pandemic globally [6]. Africa accounts for about 2.8% (198,553) of the total
confirmed cases (7,039,918) and 1.3% (5,372) of the total confirmed deaths (404,396)
[6]. Based on the analysis of Gilbert et al. [7], Algeria, Egypt, and South Africa were
identified to have the highest importation risk andmoderate to high capacity in outbreak
responsiveness; and nations like Nigeria, Sudan, Ethiopia, Ghana, Angola, Tanzania, and
Kenya to have the variable capacity in outbreak responsiveness and high vulnerability.
Congruent to this analysis [6] is also a high prevalence of COVID-19 cases recorded
in countries with highest importation risk like South Africa (50,879), Egypt (35,444),
Morocco (8,302), and Algeria (10,265); and not a corresponding high vulnerability in
countries like Nigeria (12,801), Ethiopia (2,156), Sudan (6,244), Angola (92), Tanzania
(509), Ghana (9,910), and Kenya (2,862) [6]. However, a nation’s vulnerability is not
dependent on certain indicators but it is a function of its willingness to observe and
apply stringent control measures key to containing the spread of this pandemic.
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2. Control and prevention
The fight against COVID-19 has to be a concerted effort by all. COVID-19 spreads rapidly
and there is sustained local transmission making it impossible to isolate all cases; this
calls for the use of mitigation measures to be put in place with the objective of slowing
down the spread of the virus within a country or a region. These measures include:
the banning of mass gathering events such as sporting, political, social, and large
religious gatherings, and closure of schools, targeted at avoiding the multiplication
of cases that will overburden healthcare systems. The WHO therefore recommends:
frequent washing of hands with soap for 20 sec; maintaining physical distancing of
at least 1 m or 3 ft ; avoidance of touching eyes, nose, and mouth; regular practice
of respiratory hygiene of using a handkerchief or tissue paper when sneezing or
coughing or otherwise a flexing or bending the elbow; seeking medical care early in
the event of symptom manifestation; and staying informed and following advice given
by the healthcare professionals [8]. In the WHO recommendation, there is, therefore, an
emphasis on hygiene as a major means of breaking transmission of COVID-19. COVID-
19 outbreak is overwhelming nations, hence, the need for the application of stringent
multiple control measures by other countries struggling to contain the pandemic as
was implemented by China [8]. Xifeng, Xiaolin, and Xuchu [9] outlined six key lessons
the international community could learn from China in halting the spread of SARS-CoV-
2; they include: speed and accuracy in the identification and detection of COVID-19
carriers; making the right decisions for the right people at the right time and at the right
place; big data and information technology are important to avoid a rebound; appraising
medical resources and response systems; enforcement of precautionary measures in
schools, businesses, government offices, homes, and communities can control the
trajectory of this epidemic; and keeping the public well-informed. Preparedness is key
to mitigating the effect of COVID-19 at national and local levels.
A human clinical trial to evaluate an investigational vaccine mRNA-1273 designed to
protect against SARS-CoV-2 is ongoing at the Kaiser Permanente Washington Health
Research Institute (KPWHRI) [10]. Recently, a body of evidence has emerged about
the possibility of using BCG (Bacillus Calmette-Guerin) vaccine given to counter TB
as protection against COVID-19. A correlation study of 178 countries has shown that
nations with BCG vaccination program have fewer COVID-19 cases in comparison to
where BCG programs are no longer deployed [11]. Moorlag et al. (2019) reported that
BCG vaccine induces heterologous immunity against other infections including viral
infections [12], and previous research had also provided evidence that BCG vaccine
reduced respiratory tract infections in adolescents [13]. However, the WHO does not yet
recommend BCG vaccination for the prevention of COVID-19 and is presently testing
the theory with human clinical trials on selected cohorts concerning the success theory
of BCG vaccination to forestall COVID-19 [14]. Also, randomized controlled clinical trials
are currently ongoing in the Netherlands and Australia to substantiate the use of BCG
for COVID-19 prevention (NCT04327206, NCT04328441). Indeed, a safe and potent
vaccine to protect against SARS-CoV-2 infection will be a very important step toward
fighting the spread of this contagion.
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3. Therapeutic prospects
Of note, the COVID-19 broke out in China and spread in Iran, Italy, and the rest of
Europe during the winter season. Viruses have a temperature range in which they
can survive for some time, and this range is dependent on their outer layer enve-
lope. Wang et al. [15] investigated how air temperature and humidity influence COVID-
19 transmission, and their findings suggest that high temperature and high humidity
remarkably reduces the transmission of COVID-19 influenza. Park et al. [16] stressed
that experiences from SARS and MERS epidemics and treatment of other endemic and
epidemic respiratory viruses could provide some guidance on the treatment strategies
that may be helpful to COVID-19 patients. The WHO laboratory work shows that heat
at 56ºC kills the SARS coronavirus at around 10,000 units per 15 min. This could pave
way for a potential therapeutic prospect of warm steam inhalation/heated humidified
air delivery/rhinothermy, which has been traditionally and clinically proven to be potent
against viral upper respiratory tract infections [17–19].
Moreover, there is currently no universally approved medication by any regulatory
agency for the treatment of COVID-19. The prevention of COVID-19 infection remains the
mainstay of containment of the pandemic. Infected people may need supportive care
to help them survive the illness. Several companies and research groups are currently
developing or testing certain drugs against the virus that causes COVID-19. Clinical
trials are currently ongoing for existing drugs like Remdesivir, Hydroxychloroquine
or Chloroquine, and Favipiravir [20, 21]. WHO instituted Solidarity trial to help find
potent therapy for COVID-19 and will compare four therapeutic alternatives against
the standard of care to determine their relative effectiveness against COVID-19 [22].
The human clinical trial aims to rapidly ascertain whether any of the prescriptions
slow disease progression or improve survival and will enroll patients in multiple coun-
tries. The treatment options selected for the study are Remdesivir; Lopinavir/Ritonavir;
Lopinavir/Ritonavir with Interferon beta-1a; and Hydroxychloroquine [22]. As of June 3,
2020, over 3,500 patients have been recruited in over 400 hospitals in 35 countries
for human clinical trials [22].
4. Conclusion
In over six months that COVID-19 has ravaged the world, over seven million people
have been affected with more than 404,396 deaths and still counting. Global economy,
government ,and business activities have been seriously affected by this pandemic as
various countries have implemented stringent control measures to contain its spread.
However, there is hope as there are potential therapeutic promises, and real com-
mitment globally to control its spread, identify and design efficacious vaccine and
therapeutics that will enable us to win SARS-CoV-2 infection war.
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